Clinical outcome of epidermal growth factor receptor-tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutations.

Thorac Cancer · 2016 · PMC4718136 · PMID 26813477

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In patients with overlapping KRAS and EGFR mutations, there were more non‐smokers (62.5%) compared to those with KRAS mutations alone (52.1%), but the difference did not reach statistical significance (Table 1 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.